말초혈관 기기 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Peripheral Vascular Devices Market Size, Share & Trends Analysis Report By Type, By Application (Peripheral Arterial Disease, Aneurysms, Venous Diseases), By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,257,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,645,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,420,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

말초혈관 기기 시장 성장 및 동향:

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 말초혈관 기기 시장 규모는 2025년부터 2030년까지 연평균 5.8%의 CAGR을 기록하여 2030년에는 148억 달러에 달할 것으로 예상됩니다.

말초동맥질환(PVD)의 유병률 증가, 임상시험 및 연구 증가, 기술 발전, 정부의 노력 등이 시장 성장을 촉진하는 요인으로 꼽힙니다. 제약회사와 의료기기 제조업체들은 말초혈관질환 PVD에 대한 혁신적인 해결책을 찾기 위해 임상시험에 자금을 지원하고 있습니다. 이러한 추세는 제품 개발 주기를 가속화하고 업계 이해관계자와 학계의 협력을 촉진하고 있습니다.

더 많은 연구가 시작됨에 따라 생성된 데이터는 이러한 기기의 성능과 효능을 개선하는 데 큰 도움이 될 것입니다. 또한, 규제 당국의 임상시험 증가에 대한 지원은 이러한 노력에 힘을 실어주고 시장에서 첨단 솔루션의 개발을 촉진할 것으로 예상됩니다. 예를 들어, 2024년 6월 AVS는 FDA로부터 박동성 혈관 내 결석파쇄(PIL) 시스템에 대한 임상시험을 실시할 수 있는 임상시험용 의료기기 면제(IDE)를 획득했습니다. 이 임상시험은 말초동맥질환 환자에서 PIL 시스템의 안전성과 유효성을 평가하기 위한 것으로, AVS는 석회화 혈관 질환을 앓고 있는 환자들을 위한 덜 침습적인 치료법 개발에 있어 중요한 발걸음을 내딛었으며, 여러 기관에서 이 임상시험을 시작할 예정입니다. 이러한 시장 기업들의 노력은 R&D 환경의 발전과 함께 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.

또한, 말초혈관 기기 시장의 경쟁 구도가 진화함에 따라 파트너십, 사업 확장, 합의, 인수 등 세계 헬스케어 부문에 이러한 첨단 기기의 제공과 가용성을 크게 향상시킬 수 있는 여러 시장 기업의 이니셔티브가 생겨났습니다. 예를 들어, 2024년 6월 보스턴 사이언티픽(Boston Scientific)은 경동맥 질환에 대한 혁신적인 솔루션을 전문으로 하는 실크로드 메디컬(Silk Road Medical)을 인수하기로 합의했다고 발표했습니다. 약 11억 달러 규모의 이번 인수는 보스턴사이언티픽의 혈관 중재술 포트폴리오를 강화하고 성장하는 경동맥 시장에서의 입지를 확대하기 위한 것입니다. 이러한 시장 진입자들의 제품 제공 확대 노력은 해당 기기의 가용성 증가와 함께 예측 기간 동안 시장 성장을 촉진할 것으로 예상됩니다.

말초혈관장치 시장 보고서 하이라이트

• 유형별로는 말초 스텐트 분야가 2024년 약 21.7%로 가장 큰 점유율을 차지했습니다. 자금 지원 및 승인 형태의 정부 지원이 증가함에 따라 제조업체는 기술적으로 진보된 말초 스텐트 개발을 장려하고 있습니다.
• 용도별로는 말초동맥질환(PAD) 분야가 2024년 45.3%에 가까운 가장 큰 점유율을 차지했습니다. 말초동맥질환의 유병률 증가와 정부의 노력이 이 부문의 성장을 주도하고 있습니다.
• 최종 용도별로는 병원 부문이 2024년 약 64.4%로 가장 큰 점유율을 차지했습니다. 병원은 경피적 경동맥 우회술(PTAB)을 포함한 고급 의료 절차를 수행하는 데 있어 매우 중요합니다.
• 북미는 2024년 38.9%의 점유율을 차지하며 말초혈관 기기를 지배했습니다. 말초혈관 기기 시장은 말초 동맥 질환(PAD) 유병률 증가, 노인 인구 증가, 의료 기술의 급속한 발전 등 여러 요인으로 인해 안정적인 성장을 보이고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 말초혈관 기기 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상부 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 견인 요인 분석
  • 시장 성장 억제요인 분석
• 말초혈관 기기 시장 분석 툴
  • 업계 분석 - Porter's Five Forces 분석
  • PESTEL 분석

제4장 말초혈관 기기 시장 : 유형 추정·동향 분석

• 말초혈관 기기 시장 : 유형 대시보드
• 말초혈관 기기 시장 : 유형 변동 분석
• 말초혈관 기기 시장 규모와 예측 및 동향 분석, 유형별, 2018-2030년
• 말초 스텐트
• PTA 풍선
• 카테터
• 혈관내 동맥류 수복 스텐트 그래프트
• 플라크 수정 장비
• 주변기기 액세서리
• 하대정맥 필터
  • 영구 필터
  • 취득 가능한 필터
• 혈역학 혈류 조절 장비
  • 만성 완전 폐색 디바이스
  • 색전보호 디바이스

제5장 말초혈관 기기 시장 : 용도 추정·동향 분석

• 말초혈관 기기 시장 : 용도 대시보드
• 말초혈관 기기 시장 : 용도 변동 분석
• 말초혈관 기기 시장 규모와 예측 및 동향 분석, 용도별, 2018-2030년
• 말초동맥질환(PAD)
• 동맥류
• 정맥 질환
• 기타

제6장 말초혈관 기기 시장 : 최종 용도 추정·동향 분석

• 말초혈관 기기 시장 : 최종 용도 대시보드
• 말초혈관 기기 시장 : 최종 용도 변동 분석
• 말초혈관 기기 시장 규모와 예측 및 동향 분석, 최종 용도별, 2018-2030년
• 병원
• 외래 수술 센터
• 기타

제7장 말초혈관 기기 시장 : 국가, 유형, 용도, 최종 용도, 지역별 지역 추정·동향 분석

• 지역 대시보드
• 시장 규모와 예측 동향 분석, 2018년에서 2030년
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트
  • 쿠웨이트

제8장 경쟁 상황

• 주요 시장 진출 기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 상황
  • 주요 판매대리점 및 채널 파트너 리스트
  • Key customers
  • Key company market share analysis, 2023
  • Abbott
  • Koninklijke Philips NV
  • Edward Lifesciences Corporation
  • Medtronic
  • Teleflex Incorporated
  • Cook Group
  • Cordis
  • Boston Scientific Corporation
  • WL Gore &Associates, Inc.
  • Biotronik
  • BD
  • Terumo Corporation

ksm

영문 목차

영문목차

Peripheral Vascular Devices Market Growth & Trends:

The global peripheral vascular devices market size is expected to reach USD 14.8 billion by 2030, registering a CAGR of 5.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The factors driving market growth are the growing prevalence of peripheral arterial disease (pad), increasing clinical trials & studies, technological advancements, and government initiatives. Pharmaceutical companies and medical device manufacturers are increasingly funding clinical trials to explore innovative solutions for peripheral vascular disease PVD. This trend accelerates product development cycles and encourages collaboration between industry stakeholders and academic institutions.

As more studies are initiated, the data generated can significantly help improve these devices' performance and effectiveness. Moreover, regulatory support for increasing clinical trials is anticipated to boost these initiatives, thereby enhancing the development of advanced solutions in the market. For instance, in June 2024, AVS received an Investigational Device Exemption (IDE) from the FDA to conduct a clinical trial for its Pulsatile Intravascular Lithotripsy (PIL) system. The trial will assess the safety and effectiveness of the PIL system in patients with peripheral artery disease. AVS plans to initiate the study across multiple sites, marking a significant step forward in developing less invasive treatment options for patients suffering from calcified vascular conditions. Such efforts by market players, coupled with the developing R&D environment, are expected to drive market growth over the forecast period.

Moreover, the evolving competitive landscape of the peripheral vascular devices market is leading to several initiatives by market players that significantly increase their offerings and availability of these advanced devices to the healthcare sector globally, such as partnerships, expansion, agreements, acquisitions, and others. For instance, in June 2024, Boston Scientific announced an agreement to acquire Silk Road Medical, Inc., specializing in innovative solutions for carotid artery disease. The acquisition, valued at approximately USD 1.1 billion, aims to enhance Boston Scientific's portfolio in vascular intervention and expand its presence in the growing carotid artery market. Such initiatives by the market players to increase their offers, coupled with the growing availability of these devices, are expected to drive market growth over the forecast period.

Peripheral Vascular Devices Market Report Highlights:

• Based on type, the peripheral stents segment held the largest share of nearly 21.7% in 2024. The rising government support in the form of funding and approvals is encouraging manufacturers to develop technologically advanced peripheral stents.
• Based on application, the peripheral arterial disease (PAD) segment held the largest share of nearly 45.3% in 2024. The rising prevalence of peripheral artery disease and government initiatives drive segment growth.
• Based on end-use, the hospitals segment held the largest share of nearly 64.4% in 2024. Hospitals are crucial in administering advanced medical procedures, including Percutaneous Transmural Arterial Bypass (PTAB).
• North America dominated the peripheral vascular devices with a share of 38.9% in 2024. The peripheral vascular devices market exhibits consistent growth owing to several factors, including the growing incidence of Peripheral Artery Disease (PAD), rising geriatric population, and rapid advancements in medical technology.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. End use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market outlook
• 2.2. Segment outlook
  • 2.2.1. Type outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Peripheral Vascular Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Growing prevalence of PAD
    • 3.2.1.2. Increasing clinical trials and studies
    • 3.2.1.3. Novel product launch
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of treatment and devices
    • 3.2.2.2. Product recalls
• 3.3. Peripheral Vascular Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Peripheral Vascular Devices Market: Type Estimates & Trend Analysis

• 4.1. Peripheral Vascular Devices Market: Type Dashboard
• 4.2. Peripheral Vascular Devices Market: Type Movement Analysis
• 4.3. Peripheral Vascular Devices Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 4.4. Peripheral Stents
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.1. Iliac Artery Stents
      • 4.4.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Femoral Artery Stents
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Carotid Artery Stents
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.4. Renal Artery Stents
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.5. Other Peripheral Stents
      • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. PTA Balloons
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Catheters
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.1.1. Angiography Catheters
      • 4.6.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.1.2. Guiding Catheters
      • 4.6.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.6.1.3. IVUS/OCT Catheters
      • 4.6.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Endovascular Aneurysm Repair Stent Grafts
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.1.1. Thoracic Endovascular Aneurysm Stent Grafts
      • 4.7.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.1.2. Abdominal Endovascular Aneurysm Stent Grafts
      • 4.7.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Plaque Modification Devices
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.1.1. Atherectomy Devices
      • 4.8.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.8.1.2. Thrombectomy Devices
      • 4.8.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Peripheral Accessories
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.9.1.1. Guidewires
      • 4.9.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.9.1.1.2. Workhorse Guidewires
        • 4.9.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.9.1.1.3. Specialty Guidewires
        • 4.9.1.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.9.1.1.4. Extra Support Guidewires
        • 4.9.1.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.9.1.1.5. Frontline Finesse Guidewires
        • 4.9.1.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.9.1.2. Peripheral Vascular Closure Devices
      • 4.9.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.9.1.3. Balloon Inflation Devices
      • 4.9.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.9.1.4. Introducer Sheaths
      • 4.9.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Inferior Vena Cava Filters
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10.2. Permanent Filters
    • 4.10.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10.3. Retrievable Filters
    • 4.10.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Hemodynamic Flow Alteration Devices
  • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11.2. Chronic Total Occlusion Devices
    • 4.11.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11.3. Embolic Protection Devices
    • 4.11.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Peripheral Vascular Devices Market: Application Estimates & Trend Analysis

• 5.1. Peripheral Vascular Devices Market: Application Dashboard
• 5.2. Peripheral Vascular Devices Market: Application Movement Analysis
• 5.3. Peripheral Vascular Devices Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Peripheral Arterial Disease (PAD)
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Aneurysms
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Venous Diseases
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Peripheral Vascular Devices Market: End Use Estimates & Trend Analysis

• 6.1. Peripheral Vascular Devices Market: End Use Dashboard
• 6.2. Peripheral Vascular Devices Market: End Use Movement Analysis
• 6.3. Peripheral Vascular Devices Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Ambulatory Surgical Centers
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Peripheral Vascular Devices Market: Regional Estimates & Trend Analysis by Country, Type , Application, End use and Region

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 7.3. North America
  • 7.3.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Regulatory framework/ reimbursement structure
    • 7.3.4.3. Competitive scenario
    • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Norway
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.9. Denmark
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Regulatory framework/ reimbursement structure
    • 7.4.9.3. Competitive scenario
    • 7.4.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework/ reimbursement structure
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Mexico
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Argentina
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Abbott
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Koninklijke Philips N.V.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Edward Lifesciences Corporation
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Medtronic
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Teleflex Incorporated
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Cook Group
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Cordis
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Boston Scientific Corporation
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. W. L. Gore & Associates, Inc.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Biotronik
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. BD
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives
  • 8.3.15. Terumo Corporation
    • 8.3.15.1. Company overview
    • 8.3.15.2. Financial performance
    • 8.3.15.3. Product benchmarking
    • 8.3.15.4. Strategic initiatives

관련자료